Immunovant (IMVT) Competitors $14.88 -0.02 (-0.10%) As of 01:09 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMVT vs. SLNO, BBIO, VRNA, ELAN, BPMC, ROIV, GRFS, LEGN, RVMD, and RYTMShould you be buying Immunovant stock or one of its competitors? The main competitors of Immunovant include Soleno Therapeutics (SLNO), BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), Elanco Animal Health (ELAN), Blueprint Medicines (BPMC), Roivant Sciences (ROIV), Grifols (GRFS), Legend Biotech (LEGN), Revolution Medicines (RVMD), and Rhythm Pharmaceuticals (RYTM). These companies are all part of the "medical" sector. Immunovant vs. Its Competitors Soleno Therapeutics BridgeBio Pharma Verona Pharma PLC American Depositary Share Elanco Animal Health Blueprint Medicines Roivant Sciences Grifols Legend Biotech Revolution Medicines Rhythm Pharmaceuticals Soleno Therapeutics (NASDAQ:SLNO) and Immunovant (NASDAQ:IMVT) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations, earnings and media sentiment. Which has better valuation & earnings, SLNO or IMVT? Soleno Therapeutics is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSoleno TherapeuticsN/AN/A-$175.85M-$4.14-16.38ImmunovantN/AN/A-$413.84M-$2.85-5.20 Do analysts rate SLNO or IMVT? Soleno Therapeutics presently has a consensus price target of $115.09, suggesting a potential upside of 69.69%. Immunovant has a consensus price target of $35.20, suggesting a potential upside of 137.44%. Given Immunovant's higher possible upside, analysts clearly believe Immunovant is more favorable than Soleno Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Soleno Therapeutics 0 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 3.08Immunovant 0 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.83 Does the media favor SLNO or IMVT? In the previous week, Soleno Therapeutics had 24 more articles in the media than Immunovant. MarketBeat recorded 29 mentions for Soleno Therapeutics and 5 mentions for Immunovant. Immunovant's average media sentiment score of 1.65 beat Soleno Therapeutics' score of 0.82 indicating that Immunovant is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Soleno Therapeutics 7 Very Positive mention(s) 5 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Immunovant 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do insiders and institutionals have more ownership in SLNO or IMVT? 97.4% of Soleno Therapeutics shares are held by institutional investors. Comparatively, 47.1% of Immunovant shares are held by institutional investors. 6.4% of Soleno Therapeutics shares are held by insiders. Comparatively, 1.8% of Immunovant shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is SLNO or IMVT more profitable? Soleno Therapeutics' return on equity of -73.74% beat Immunovant's return on equity.Company Net Margins Return on Equity Return on Assets Soleno TherapeuticsN/A -73.74% -56.67% Immunovant N/A -80.99%-72.23% Which has more volatility & risk, SLNO or IMVT? Soleno Therapeutics has a beta of -2.56, meaning that its stock price is 356% less volatile than the S&P 500. Comparatively, Immunovant has a beta of 0.66, meaning that its stock price is 34% less volatile than the S&P 500. SummarySoleno Therapeutics beats Immunovant on 8 of the 13 factors compared between the two stocks. Get Immunovant News Delivered to You Automatically Sign up to receive the latest news and ratings for IMVT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMVT vs. The Competition Export to ExcelMetricImmunovantMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.59B$3.08B$5.72B$9.73BDividend YieldN/A2.24%4.40%4.08%P/E Ratio-5.2020.6531.3725.97Price / SalesN/A344.67427.38103.88Price / CashN/A43.2325.7828.79Price / Book3.569.749.636.05Net Income-$413.84M-$54.08M$3.26B$265.28M7 Day Performance0.03%4.36%3.54%2.93%1 Month Performance-12.54%2.93%3.40%0.23%1 Year Performance-53.69%7.00%30.73%18.14% Immunovant Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMVTImmunovant2.9191 of 5 stars$14.88-0.1%$35.20+136.6%-54.1%$2.59BN/A-5.22120News CoveragePositive NewsSLNOSoleno Therapeutics4.6232 of 5 stars$68.09-4.9%$114.30+67.9%+47.0%$3.81BN/A-16.4530News CoverageBBIOBridgeBio Pharma4.6058 of 5 stars$49.02-4.5%$61.35+25.2%+86.8%$9.81B$221.90M0.00400VRNAVerona Pharma PLC American Depositary Share2.5196 of 5 stars$105.79+0.5%$109.00+3.0%+292.9%$8.96B$42.28M-106.8630Positive NewsELANElanco Animal Health3.027 of 5 stars$17.72-1.4%$17.33-2.2%+22.2%$8.92B$4.44B20.609,000News CoverageBPMCBlueprint MedicinesN/A$129.46flat$130.00+0.4%N/A$8.36B$562.12M-52.41640ROIVRoivant Sciences3.2074 of 5 stars$11.81-0.3%$16.50+39.7%-2.0%$8.06B$29.05M0.00860News CoverageGRFSGrifols3.4014 of 5 stars$10.58-1.3%$10.30-2.6%+14.5%$7.37B$7.45B9.0423,822LEGNLegend Biotech3.8857 of 5 stars$37.45-0.1%$72.38+93.3%-39.8%$6.89B$627.24M0.002,609News CoverageAnalyst ForecastRVMDRevolution Medicines4.382 of 5 stars$36.45+0.4%$69.54+90.8%-18.3%$6.79B$11.58M0.00250Positive NewsRYTMRhythm Pharmaceuticals3.7673 of 5 stars$98.09+0.5%$101.57+3.5%+115.1%$6.48B$130.13M0.00140Positive NewsInsider Trade Related Companies and Tools Related Companies SLNO Competitors BBIO Competitors VRNA Competitors ELAN Competitors BPMC Competitors ROIV Competitors GRFS Competitors LEGN Competitors RVMD Competitors RYTM Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMVT) was last updated on 8/26/2025 by MarketBeat.com Staff From Our Partners$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 30th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredHow 8,000+ investors trade crypto with a 93% win rateThere are 18,347 cryptocurrencies in the market right now. 99% of them will fail. And trying to pick winner...Crypto Swap Profits | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunovant, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunovant With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access